{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T09:58:49Z","timestamp":1785491929505,"version":"3.56.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004731","name":"Zhejiang Province Natural Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Regional Health - Western Pacific"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.lanwpc.2026.101916","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T15:11:52Z","timestamp":1783955512000},"page":"101916","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Low-dose chidamide maintenance therapy following allogeneic hematopoietic cell transplantation in T-cell acute lymphoblastic leukemia or lymphomas: a phase II, open-label, multicenter, single-arm trial"],"prefix":"10.1016","volume":"72","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3857-5574","authenticated-orcid":false,"given":"Yanmin","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huarui","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizhen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guifang","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimin","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixia","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijie","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2723-1621","authenticated-orcid":false,"given":"He","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"25","key":"10.1016\/j.lanwpc.2026.101916_bib1","doi-asserted-by":"crossref","first-page":"5136","DOI":"10.1182\/blood-2009-08-231217","article-title":"T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII\/ECOG 2993)","volume":"114","author":"Marks","year":"2009","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.lanwpc.2026.101916_bib2","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1182\/blood.2023021787","article-title":"New insights into the biology of T-cell lymphomas","volume":"144","author":"Iqbal","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.lanwpc.2026.101916_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217664","article-title":"Allogeneic versus autologous hematopoietic stem cell transplantation for adult T-lymphoblastic lymphoma: a real-world multicenter analysis in China","volume":"621","author":"Wang","year":"2025","journal-title":"Cancer Lett"},{"issue":"3","key":"10.1016\/j.lanwpc.2026.101916_bib4","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1182\/blood-2018-01-791335","article-title":"Allogeneic hematopoietic stem cell transplantation for T-cell lymphomas","volume":"132","author":"Schmitz","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.lanwpc.2026.101916_bib5","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13045-020-00892-4","article-title":"Allogeneic stem cell transplantation for peripheral T cell lymphomas: a retrospective study in 285 patients from the Soci\u00e9t\u00e9 Francophone de Greffe de Moelle et de Th\u00e9rapie Cellulaire (SFGM-TC)","volume":"13","author":"Mamez","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"6","key":"10.1016\/j.lanwpc.2026.101916_bib6","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1038\/leu.2012.352","article-title":"Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia","volume":"27","author":"Pfeifer","year":"2013","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.lanwpc.2026.101916_bib7","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/S1470-2045(20)30455-1","article-title":"Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial","volume":"21","author":"Xuan","year":"2020","journal-title":"Lancet Oncol"},{"issue":"26","key":"10.1016\/j.lanwpc.2026.101916_bib8","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1200\/JCO.19.03345","article-title":"Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-Internal tandem duplication mutation (SORMAIN)","volume":"38","author":"Burchert","year":"2020","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.lanwpc.2026.101916_bib9","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1200\/JCO.23.02474","article-title":"Gilteritinib as post-transplant maintenance for AML with internal tandem duplication mutation of FLT3","volume":"42","author":"Levis","year":"2024","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.lanwpc.2026.101916_bib10","doi-asserted-by":"crossref","first-page":"e448","DOI":"10.1016\/S2352-3026(24)00098-X","article-title":"Donor lymphocyte infusion after allogeneic haematopoietic cell transplantation for haematological malignancies: basic considerations and best practice recommendations from the EBMT","volume":"11","author":"Pagliuca","year":"2024","journal-title":"Lancet Haematol"},{"issue":"21","key":"10.1016\/j.lanwpc.2026.101916_bib11","doi-asserted-by":"crossref","first-page":"5580","DOI":"10.1182\/bloodadvances.2020002544","article-title":"A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients","volume":"4","author":"Oran","year":"2020","journal-title":"Blood Adv"},{"issue":"36","key":"10.1016\/j.lanwpc.2026.101916_bib12","doi-asserted-by":"crossref","first-page":"4249","DOI":"10.1200\/JCO.19.03277","article-title":"Effect of rhG-CSF combined with decitabine prophylaxis on relapse of patients with high-risk MRD-Negative AML after HSCT: an open-label, multicenter, randomized controlled trial","volume":"38","author":"Gao","year":"2020","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.lanwpc.2026.101916_bib13","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s00280-011-1766-x","article-title":"Chidamide (CS055\/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity","volume":"69","author":"Ning","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"issue":"8","key":"10.1016\/j.lanwpc.2026.101916_bib14","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1093\/annonc\/mdv237","article-title":"Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma","volume":"26","author":"Shi","year":"2015","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.lanwpc.2026.101916_bib15","doi-asserted-by":"crossref","first-page":"811","DOI":"10.3324\/haematol.2022.280996","article-title":"Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb results","volume":"108","author":"Rai","year":"2023","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.lanwpc.2026.101916_bib16","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1002\/ajh.26499","article-title":"Chidamide plus prednisone, etoposide, and thalidomide for untreated angioimmunoblastic T-cell lymphoma in a Chinese population: a multicenter phase II trial","volume":"97","author":"Wang","year":"2022","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.lanwpc.2026.101916_bib17","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1080\/10428194.2019.1691195","article-title":"Chidamide in combination with chemotherapy in refractory and relapsed T lymphoblastic lymphoma\/leukemia","volume":"61","author":"Guan","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"10.1016\/j.lanwpc.2026.101916_bib18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0070522","article-title":"Increased PRAME-specific CTL killing of acute myeloid leukemia cells by either a novel histone deacetylase inhibitor chidamide alone or combined treatment with decitabine","volume":"8","author":"Yao","year":"2013","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.lanwpc.2026.101916_bib19","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1182\/bloodadvances.2018027003","article-title":"The impact of the graft-versus-leukemia effect on survival in acute lymphoblastic leukemia","volume":"3","author":"Yeshurun","year":"2019","journal-title":"Blood Adv"},{"issue":"32","key":"10.1016\/j.lanwpc.2026.101916_bib20","doi-asserted-by":"crossref","first-page":"3788","DOI":"10.1200\/JCO.24.00554","article-title":"Long-Term Follow-Up of the prospective randomized AATT Study (Autologous or Allogeneic Transplantation in Patients With Peripheral T-Cell Lymphoma)","volume":"42","author":"Tournilhac","year":"2024","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.lanwpc.2026.101916_bib21","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s41571-020-0356-4","article-title":"Dissecting the biology of allogeneic HSCT to enhance the GvT effect whilst minimizing GvHD","volume":"17","author":"Blazar","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"issue":"17","key":"10.1016\/j.lanwpc.2026.101916_bib22","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1182\/blood-2014-04-571570","article-title":"T-cell-replete haploidentical HSCT with low-dose anti-T-lymphocyte globulin compared with matched sibling HSCT and unrelated HSCT","volume":"124","author":"Luo","year":"2014","journal-title":"Blood"},{"issue":"27","key":"10.1016\/j.lanwpc.2026.101916_bib23","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.lanwpc.2026.101916_bib24","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report","volume":"11","author":"Filipovich","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.lanwpc.2026.101916_bib25","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","article-title":"International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai Acute GVHD International Consortium","volume":"22","author":"Harris","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.lanwpc.2026.101916_bib26","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working Group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"10.1016\/j.lanwpc.2026.101916_bib27","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1038\/s41409-018-0184-7","article-title":"Allogeneic hematopoietic stem cell transplantation should be in preference to conventional chemotherapy as post-remission treatment for adults with lymphoblastic lymphoma","volume":"53","author":"Yang","year":"2018","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.lanwpc.2026.101916_bib28","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s13148-020-00962-x","article-title":"Epigenetic alterations and advancement of treatment in peripheral T-cell lymphoma","volume":"12","author":"Zhang","year":"2020","journal-title":"Clin Epigenetics"},{"issue":"10","key":"10.1016\/j.lanwpc.2026.101916_bib29","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.leukres.2013.07.016","article-title":"The expression of histone deacetylase 4 is associated with prednisone poor-response in childhood acute lymphoblastic leukemia","volume":"37","author":"Gruhn","year":"2013","journal-title":"Leuk Res"},{"issue":"2","key":"10.1016\/j.lanwpc.2026.101916_bib30","doi-asserted-by":"crossref","first-page":"142","DOI":"10.4132\/KoreanJPathol.2012.46.2.142","article-title":"Expression of HAT1 and HDAC1, 2, 3 in diffuse large B-Cell lymphomas, peripheral T-Cell lymphomas, and NK\/T-Cell lymphomas","volume":"46","author":"Min","year":"2012","journal-title":"Korean J Pathol"},{"issue":"6","key":"10.1016\/j.lanwpc.2026.101916_bib31","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1111\/j.1365-2559.2009.03290.x","article-title":"Histone deacetylase 1, 2, 6 and acetylated histone H4 in B- and T-cell lymphomas","volume":"54","author":"Marquard","year":"2009","journal-title":"Histopathology"},{"issue":"10","key":"10.1016\/j.lanwpc.2026.101916_bib32","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1097\/CM9.0000000000003214","article-title":"Chidamide triggers pyroptosis in T-cell lymphoblastic lymphoma\/leukemia via the FOXO1\/GSDME axis","volume":"138","author":"Li","year":"2025","journal-title":"Chin Med J"},{"issue":"3","key":"10.1016\/j.lanwpc.2026.101916_bib33","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1007\/s11684-021-0877-y","article-title":"Chidamide inhibits the NOTCH1-MYC signaling axis in T-cell acute lymphoblastic leukemia","volume":"16","author":"Xi","year":"2022","journal-title":"Front Med"},{"issue":"7","key":"10.1016\/j.lanwpc.2026.101916_bib34","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1080\/10428194.2024.2328227","article-title":"Chidamide enhances T-cell-mediated anti-tumor immune function by inhibiting NOTCH1\/NFATC1 signaling pathway in ABC-type diffuse large B-cell lymphoma","volume":"65","author":"Li","year":"2024","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.lanwpc.2026.101916_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104420","article-title":"Histone deacetylases inhibitor chidamide synergizes with humanized PD1 antibody to enhance T-cell chemokine expression and augment Ifn-\u03b3 response in NK-T cell lymphoma","volume":"87","author":"Wen","year":"2023","journal-title":"eBioMedicine"},{"issue":"11","key":"10.1016\/j.lanwpc.2026.101916_bib36","doi-asserted-by":"crossref","first-page":"3921","DOI":"10.1073\/pnas.0400380101","article-title":"Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect","volume":"101","author":"Reddy","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"10.1016\/j.lanwpc.2026.101916_bib37","first-page":"2562","article-title":"Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase-dependent DC functions and regulates experimental graft-versus-host disease in mice","volume":"118","author":"Reddy","year":"2008","journal-title":"J Clin Invest"},{"issue":"11","key":"10.1016\/j.lanwpc.2026.101916_bib38","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/nm1652","article-title":"Deacetylase inhibition promotes the generation and function of regulatory T cells","volume":"13","author":"Tao","year":"2007","journal-title":"Nat Med"}],"container-title":["The Lancet Regional Health - Western Pacific"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666606526001203?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666606526001203?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T09:18:01Z","timestamp":1785489481000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666606526001203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":38,"alternative-id":["S2666606526001203"],"URL":"https:\/\/doi.org\/10.1016\/j.lanwpc.2026.101916","relation":{},"ISSN":["2666-6065"],"issn-type":[{"value":"2666-6065","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low-dose chidamide maintenance therapy following allogeneic hematopoietic cell transplantation in T-cell acute lymphoblastic leukemia or lymphomas: a phase II, open-label, multicenter, single-arm trial","name":"articletitle","label":"Article Title"},{"value":"The Lancet Regional Health - Western Pacific","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lanwpc.2026.101916","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101916"}}